Overview

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in first-line treatment of patients with hepatocellular carcinoma.

Phase:

PHASE1

Details

Lead Sponsor:

Beijing 302 Hospital

Collaborators:

Beijing GD Initiative Cell Therapy Technology Co., Ltd.
Chinese Academy of Medical Sciences

Treatments:

spartalizumab